Ligand Pharmaceuticals, Inc. (LGND)
280.60
-3.92
(-1.38%)
USD |
NASDAQ |
Aug 28, 16:00
280.60
0.00 (0.00%)
After-Hours: 19:32
Ligand Pharmaceuticals Cash from Operations (Quarterly) : 24.02M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 24.02M |
| March 31, 2026 | 48.69M |
| December 31, 2025 | 45.92M |
| September 30, 2025 | 13.16M |
| June 30, 2025 | 15.80M |
| March 31, 2025 | -25.52M |
| December 31, 2024 | 28.35M |
| September 30, 2024 | 36.32M |
| June 30, 2024 | 13.26M |
| March 31, 2024 | 18.69M |
| December 31, 2023 | 7.116M |
| September 30, 2023 | 7.646M |
| June 30, 2023 | -0.082M |
| March 31, 2023 | 33.95M |
| December 31, 2022 | 53.47M |
| September 30, 2022 | 20.49M |
| June 30, 2022 | 11.88M |
| March 31, 2022 | 52.01M |
| December 31, 2021 | 27.64M |
| September 30, 2021 | 20.02M |
| June 30, 2021 | 20.38M |
| March 31, 2021 | 10.75M |
| December 31, 2020 | 0.537M |
| September 30, 2020 | 12.74M |
| June 30, 2020 | 24.38M |
| Date | Value |
|---|---|
| March 31, 2020 | 16.92M |
| December 31, 2019 | -7.339M |
| September 30, 2019 | -6.197M |
| June 30, 2019 | -61.06M |
| March 31, 2019 | 45.26M |
| December 31, 2018 | 32.57M |
| September 30, 2018 | 27.08M |
| June 30, 2018 | 73.64M |
| March 31, 2018 | 60.76M |
| December 31, 2017 | 36.31M |
| September 30, 2017 | 27.65M |
| June 30, 2017 | 5.388M |
| March 31, 2017 | 24.22M |
| December 31, 2016 | 20.99M |
| September 30, 2016 | 18.52M |
| June 30, 2016 | 10.37M |
| March 31, 2016 | 13.11M |
| December 31, 2015 | 13.06M |
| September 30, 2015 | 10.44M |
| June 30, 2015 | 10.05M |
| March 31, 2015 | 6.918M |
| December 31, 2014 | 10.25M |
| September 30, 2014 | 3.735M |
| June 30, 2014 | 4.008M |
| March 31, 2014 | 2.577M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Johnson & Johnson | 8.616B |
| Eli Lilly & Co. | 10.69B |
| Merck & Co., Inc. | 5.37B |
| Zevra Therapeutics, Inc. | 17.03M |
| Liquidia Corp. | 80.24M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 321.12M |
| Cash from Financing (Quarterly) | 546.43M |
| Free Cash Flow | 119.83M |
| Free Cash Flow Per Share (Quarterly) | 0.9778 |
| Free Cash Flow to Equity (Quarterly) | -658.12M |
| Free Cash Flow to Firm (Quarterly) | 22.67M |
| Free Cash Flow Yield | 2.05% |